Trial Profile
Beneficial Effect of Dose Escalation of Octreotide-LAR as First-Line Therapy in Patients With Resistant Acromegaly
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Octreotide (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- Acronyms HDacro
- 02 Jun 2015 New trial record